Stuart Homer, MD
Nephrology · Avenel, NJNPI 1760488373
Payments from drug & device makers
Across 265 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$737
- Bayer$402
- Novo Nordisk$349
- Amgen$305
- Fresenius USA Marketing, Inc.$259
- Boehringer Ingelheim$189
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,37799%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 50 | $737 |
| Bayer | 17 | $402 |
| Novo Nordisk | 22 | $349 |
| Amgen(2 entities) | 20 | $305 |
| Fresenius USA Marketing, Inc. | 16 | $259 |
| Boehringer Ingelheim | 13 | $189 |
| OPKO Pharmaceuticals, LLC | 13 | $183 |
| Vifor Pharma, Inc. | 11 | $176 |
| Otsuka America Pharmaceutical, Inc. | 9 | $136 |
| Novartis | 8 | $131 |
| Aurinia Pharma U.S., Inc. | 7 | $119 |
| Baxter Healthcare | 2 | $118 |
| Ardelyx, Inc. | 6 | $111 |
| Daiichi Sankyo Inc. | 7 | $106 |
| GSK | 6 | $99 |
| Merck | 7 | $97 |
| Calliditas Therapeutics US Inc. | 5 | $96 |
| Nxstage Medical, Inc. | 1 | $95 |
| Travere Therapeutics, Inc. | 5 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $80 |
| Mallinckrodt Hospital Products Inc. | 4 | $69 |
| Lilly USA, LLC | 5 | $68 |
| Akebia Therapeutics Inc | 4 | $66 |
| Amarin Pharma, Inc. | 3 | $41 |
| Mallinckrodt Enterprises LLC | 3 | $39 |
| Abbott | 2 | $39 |
| Pfizer | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Fresenius USA Manufacturing, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$4,411 in reported general payments places this provider in the 80th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 245 | $262,872 |
| JardianceEmpagliflozin | 190 | $207,379 |
| OzempicSemaglutide | 95 | $157,182 |
| EliquisApixaban | 76 | $83,188 |
| KerendiaFinerenone | 51 | $60,607 |
| XphozahTenapanor Hcl | 13 | $37,330 |
| LokelmaSodium Zirconium Cyclosilicate | 41 | $33,061 |
| XareltoRivaroxaban | 30 | $26,357 |
| RybelsusSemaglutide | 14 | $26,238 |
| JanuviaSitagliptin Phosphate | 25 | $25,723 |
| TestimTestosterone | 13 | $23,216 |
| MounjaroTirzepatide | 18 | $19,960 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $17,075 |
| EntrestoSacubitril/Valsartan | 15 | $14,301 |
| TradjentaLinagliptin | 18 | $13,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Symbicort | $737 | $298,800298 claims |
| Boehringer IngelheimJardiance, Tradjenta | $189 | $220,543208 claims |
| Novo NordiskOzempic, Rybelsus | $349 | $183,420109 claims |
| PfizerEliquis | $39 | $83,18876 claims |
| BayerKerendia | $402 | $60,60751 claims |
| MerckJanuvia | $97 | $25,72325 claims |
| Lilly USA, LLCMounjaro | $68 | $19,96018 claims |
| GSKBreo Ellipta | $99 | $17,07531 claims |
| NovartisEntresto | $131 | $14,30115 claims |
| Sanofi-aventis U.S. LLCMultaq | $29 | $12,84112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Avenel
- Danny HaddadJersey City$1.7M
- Anup PatelWest Orange$1M
- Joshua KaplanNewark$509K
- Lawrence ByrdLivingston$338K
- Devang LodhaviaVoorhees$321K
- Jeffrey FeldmanUnion$315K
- Kenneth LissEatontown$271K
- Narender GoelJersey City$181K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.